reserpine has been researched along with Parkinsonian Disorders in 53 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 5.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| " In this study we seek to determine ventilation and its responses to hypoxia in a reserpine--alpha-methyl-tyrosine model of parkinsonism in the rat." | 3.83 | Breathing in Parkinsonism in the Rat. ( Bialkowska, M; Boguszewski, P; Pokorski, M, 2016) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "Behavioral responses in the catalepsy, open-field, and oral movements' tests were coupled with blood pressure, body weight, and striatal tyrosine hydroxylase (TH) level assessments to establish neurobiological comparisons between reserpine-induced impairments and genetic backgrounds RESULTS: Results revealed the SHR strain was more sensitive in the catalepsy test and exhibited higher TH immunoreactivity in the dorsal striatum." | 1.91 | Genetic effects in a progressive model of parkinsonism induced by reserpine. ( Anjos, PAR; de Gois, AM; Fadanni, GP; Granzotto, N; Izídio, GS; Leão, AHFF; Linder, ÁE; Pereira, AG; Santos, JR; Silva, RH, 2023) |
| " This study evaluated the effect of chronic administration of testosterone propionate (TP) on motor behavior and neurochemical parameters in the reserpine-induced rat model of parkinsonism." | 1.72 | Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease. ( Bispo, JMM; Franco, HS; Gois, AM; Leal, PC; Lins, LCRF; Medeiros, KAAL; Melo, JEC; Ribeiro, AM; Santos, JR; Silva, RH; Silva, RS; Souza, MF, 2022) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 1.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| "Carvacrol (CA) is a phenolic monoterpene found in essential oils of many aromatic plants that presents antioxidant and neuroprotective effects." | 1.48 | Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine. ( Andrade, RAS; Bispo, JMM; Gois, AM; Lins, LCRF; Marchioro, M; Melo, TCS; Quintans-Junior, LJ; Ribeiro, AM; Santos, JR; Silva, RH; Souza, MF, 2018) |
| " Assessment of the effects of chronic administration of Diol (20mg/kg) and L-DOPA to animals with 6-OHDA-induced PS showed that administration of Diol alleviated the symptoms of sensorimotor deficit in right limbs in rats." | 1.46 | Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models. ( Ardashov, O; Ivanova, Е; Kapitsa, I; Khazanov, V; Salakhutdinov, N; Valdman, E; Volcho, K; Voronina, TI, 2017) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism." | 1.33 | Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice. ( Kulkarni, SK; Kumar, A, 2006) |
| "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0." | 1.31 | Behavioral effects of MK-801 on reserpine-treated mice. ( Andreatini, R; Andreazza, AP; Dutra, RC; Tufik, S; Vital, MA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (41.51) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (22.64) | 29.6817 |
| 2010's | 14 (26.42) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Beserra-Filho, JIA | 1 |
| Maria-Macêdo, A | 1 |
| Silva-Martins, S | 1 |
| Custódio-Silva, AC | 1 |
| Soares-Silva, B | 1 |
| Silva, SP | 1 |
| Lambertucci, RH | 1 |
| de Souza Araújo, AA | 1 |
| Lucchese, AM | 1 |
| Quintans-Júnior, LJ | 2 |
| Santos, JR | 9 |
| Silva, RH | 10 |
| Ribeiro, AM | 8 |
| Bispo, JMM | 6 |
| Melo, JEC | 3 |
| Gois, AM | 5 |
| Medeiros, KAAL | 2 |
| Silva, RS | 1 |
| Leal, PC | 4 |
| Franco, HS | 2 |
| Souza, MF | 4 |
| Lins, LCRF | 5 |
| Santos, TFO | 1 |
| Santos, RS | 1 |
| Monteiro, MCN | 1 |
| Mendonça, MS | 1 |
| Marchioro, M | 5 |
| Marano, M | 1 |
| Fadanni, GP | 1 |
| Leão, AHFF | 1 |
| Granzotto, N | 1 |
| Pereira, AG | 1 |
| de Gois, AM | 1 |
| Anjos, PAR | 1 |
| Linder, ÁE | 1 |
| Izídio, GS | 1 |
| Campêlo, CLC | 1 |
| Silva, AF | 1 |
| Dierschnabel, AL | 1 |
| Pontes, A | 1 |
| Cavalcante, JS | 1 |
| Valdman, E | 1 |
| Kapitsa, I | 1 |
| Ivanova, Е | 1 |
| Voronina, TI | 1 |
| Ardashov, O | 1 |
| Volcho, K | 1 |
| Khazanov, V | 1 |
| Salakhutdinov, N | 1 |
| Melo, TCS | 1 |
| Andrade, RAS | 1 |
| Engelberth, RCGJ | 1 |
| de A Silva, KD | 1 |
| Meurer, YR | 1 |
| Moore, C | 1 |
| Meshul, CK | 1 |
| Menezes, EC | 1 |
| Santos, PR | 1 |
| Goes, TC | 1 |
| Carvalho, VCB | 1 |
| Teixeira-Silva, F | 1 |
| Stevens, HE | 1 |
| Badauê-Passos, DJ | 1 |
| Modi, G | 1 |
| Voshavar, C | 1 |
| Gogoi, S | 1 |
| Shah, M | 1 |
| Antonio, T | 1 |
| Reith, ME | 1 |
| Dutta, AK | 1 |
| Bialkowska, M | 1 |
| Boguszewski, P | 1 |
| Pokorski, M | 1 |
| Tanabe, M | 1 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Ferger, B | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Volta, M | 2 |
| Mabrouk, OS | 1 |
| Bido, S | 1 |
| Marti, M | 2 |
| Morari, M | 2 |
| Barcelos, RC | 1 |
| Benvegnú, DM | 1 |
| Boufleur, N | 1 |
| Pase, C | 1 |
| Teixeira, AM | 1 |
| Reckziegel, P | 1 |
| Emanuelli, T | 1 |
| da Rocha, JB | 1 |
| Bürger, ME | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Mela, F | 1 |
| Budri, M | 1 |
| Malfacini, D | 1 |
| Molinari, S | 1 |
| Zaveri, NT | 1 |
| Ronzoni, S | 1 |
| Petrillo, P | 1 |
| Calò, G | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 1 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| BENTE, D | 1 |
| ITIL, T | 1 |
| RASHKIS, HA | 1 |
| SMARR, ER | 1 |
| FREYHAN, FA | 1 |
| GIBERTI, F | 1 |
| GIANNIOTTI, G | 1 |
| SPIZZIRRI, S | 1 |
| BAYREUTHER, H | 1 |
| KNAUF, HW | 1 |
| CAHAN, RB | 1 |
| PARRISH, DD | 1 |
| GUGGENHEIM, P | 1 |
| COHEN, L | 1 |
| MARKHAM, CH | 1 |
| CLARK, WG | 1 |
| WINTERS, WD | 1 |
| NEHLIL, J | 1 |
| SCHWARTZ, W | 1 |
| TURNER, JW | 1 |
| MACKIEWICZ, J | 1 |
| GERSHON, S | 1 |
| STEG, G | 1 |
| PATTEN, BM | 1 |
| SAKAMOTO, A | 1 |
| VANWOERT, MH | 1 |
| PAPAVASILIOU, PS | 1 |
| COTZIAS, GC | 1 |
| GEORGIADES, G | 1 |
| KYRATSOS, C | 1 |
| MICHAILIDES, G | 1 |
| TSINOPOULOS, T | 1 |
| ZSCHUCKE, CF | 1 |
| HUNTER, R | 1 |
| EARL, CJ | 1 |
| THRONICROFT, S | 1 |
| DESCHAEPDRYVER, A | 1 |
| LAVERTY, R | 1 |
| SHARMAN, DF | 1 |
| BIRKMAYER, W | 1 |
| HORNYKIEWICZ, O | 1 |
| MALONE, MH | 1 |
| ARZT, FC | 1 |
| BRAGAN, RA | 1 |
| DECATO, L | 1 |
| Garcia, L | 1 |
| Audin, J | 1 |
| D'Alessandro, G | 1 |
| Bioulac, B | 1 |
| Hammond, C | 1 |
| Kumar, A | 1 |
| Kulkarni, SK | 1 |
| Carvalho, RC | 1 |
| Patti, CC | 1 |
| Takatsu-Coleman, AL | 1 |
| Kameda, SR | 1 |
| Souza, CF | 1 |
| Garcez-do-Carmo, L | 1 |
| Abílio, VC | 1 |
| Frussa-Filho, R | 1 |
| Milioli, EM | 1 |
| Cologni, P | 1 |
| Santos, CC | 1 |
| Marcos, TD | 1 |
| Yunes, VM | 1 |
| Fernandes, MS | 1 |
| Schoenfelder, T | 1 |
| Costa-Campos, L | 1 |
| Fukuzaki, K | 1 |
| Kamenosono, T | 1 |
| Nagata, R | 1 |
| Di Marzo, V | 1 |
| Hill, MP | 1 |
| Bisogno, T | 1 |
| Crossman, AR | 2 |
| Brotchie, JM | 2 |
| Wardas, J | 1 |
| Konieczny, J | 1 |
| Lorenc-Koci, E | 1 |
| Hille, CJ | 1 |
| Fox, SH | 1 |
| Maneuf, YP | 1 |
| Fernagut, PO | 1 |
| Diguet, E | 1 |
| Labattu, B | 1 |
| Tison, F | 1 |
| Dutra, RC | 1 |
| Andreazza, AP | 1 |
| Andreatini, R | 1 |
| Tufik, S | 1 |
| Vital, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for reserpine and Parkinsonian Disorders
| Article | Year |
|---|---|
[PSYCHOPHARMACA: OBSERVATIONS AND INTERPRETATIONS].
Topics: Amphetamine; Amphetamines; Caudate Nucleus; Central Nervous System Stimulants; Chlorpromazine; Dihyd | 1964 |
52 other studies available for reserpine and Parkinsonian Disorders
| Article | Year |
|---|---|
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism.
Topics: alpha-Synuclein; Animals; Antioxidants; beta-Cyclodextrins; Disease Models, Animal; Dopaminergic Neu | 2022 |
Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Female; Humans; Male; Motor Activity; Parkinson Disease; | 2022 |
Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism.
Topics: Aging; Animals; Catalepsy; Disease Models, Animal; Dopamine; Male; Motor Activity; Motor Disorders; | 2022 |
Reserpine induced parkinsonism, a hidden threat of herbal medicine.
Topics: Humans; Parkinson Disease; Parkinsonian Disorders; Plant Extracts; Plants, Medicinal; Reserpine | 2023 |
Genetic effects in a progressive model of parkinsonism induced by reserpine.
Topics: Animals; Behavior, Animal; Catalepsy; Male; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rats, In | 2023 |
Exposure to an enriched environment facilitates motor recovery and prevents short-term memory impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in mice.
Topics: Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Catalepsy; Corpus Striatum; Disease | 2017 |
Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models.
Topics: Animals; Antiparkinson Agents; Catalepsy; Cyclohexanols; Disease Models, Animal; Male; Mice; Mice, I | 2017 |
Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine.
Topics: Analysis of Variance; Animals; Antiparasitic Agents; Antipsychotic Agents; Catalepsy; Cymenes; Disea | 2018 |
Serotonergic dysfunction in a model of parkinsonism induced by reserpine.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain; Male; Parkinsonian Disorders; Rats; Rats, Wistar; Rese | 2019 |
Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism.
Topics: Animals; Anxiety; Brain; CA1 Region, Hippocampal; Cognition; Corpus Striatum; Disease Models, Animal | 2019 |
Sex differences in the progressive model of parkinsonism induced by reserpine in rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Male; Motor Ac | 2019 |
Effects of a rat model of gestational hypothyroidism on forebrain dopaminergic, GABAergic, and serotonergic systems and related behaviors.
Topics: Amygdala; Animals; Anxiety; Anxiety Disorders; Disease Models, Animal; Dopamine; Dopaminergic Neuron | 2019 |
Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetul | 2014 |
Breathing in Parkinsonism in the Rat.
Topics: alpha-Methyltyrosine; Animals; Brain; Carotid Body; Disease Models, Animal; Dopamine; Dopamine Agoni | 2016 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
Topics: Animals; Benzimidazoles; Dose-Response Relationship, Drug; Excitatory Amino Acids; Mice; Mice, Knock | 2010 |
Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats.
Topics: Animals; Catalepsy; Dietary Supplements; Disease Models, Animal; Fish Oils; Male; Movement Disorders | 2011 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calcium; CHO Cells; Cricetinae; Cricetulus; Cyclohe | 2013 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
[The effects of high-dosed reserpin (serpasil) treatment and drug-induced parkinsonism-like states on the electroencephalogram].
Topics: Antihypertensive Agents; Chlorpromazine; Electroencephalography; Humans; Parkinson Disease; Parkinso | 1955 |
Protection against reserpine-induced Parkinsonism.
Topics: Humans; Parkinson Disease; Parkinsonian Disorders; Reserpine; Trihexyphenidyl | 1957 |
Psychomotility and parkinsonism in treatment with neuroleptic drugs.
Topics: Antipsychotic Agents; Chlorpromazine; Electroconvulsive Therapy; Humans; Mental Disorders; Movement; | 1957 |
[Further results of new therapy of Parkinsonian syndromes; therapeutic action of 3-phenyl-3-b-diethylamino-ethyl-2-6-dioxy-piperidine hydrochloride administered alone and with reserpine and ritalin].
Topics: Methylphenidate; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Piperidines; Reserpi | 1957 |
[The significance of reserpine-induced parkinsonism for the treatment of schizophrenia].
Topics: Parkinson Disease; Parkinsonian Disorders; Reserpine; Schizophrenia | 1958 |
[Treatment of parkinsonism-like syndromes caused by reserpine & chlorpromazine].
Topics: Chlorpromazine; Humans; Parkinson Disease; Parkinsonian Disorders; Piperidines; Reserpine; Syndrome | 1958 |
Reversibility of drug-induced parkinsonism.
Topics: Chlorpromazine; Parkinson Disease; Parkinsonian Disorders; Reserpine | 1960 |
Theoretical considerations in parkinsonism induced by tranquilizing drugs.
Topics: Chlorpromazine; Parkinson Disease; Parkinsonian Disorders; Reserpine; Tranquilizing Agents | 1959 |
EFFECT OF ALPHA-METHYL DOPA AND RESERPINE IN HUNTINGTON'S CHOREA, PARKINSON'S DISEASE AND OTHER MOVEMENT DISORDERS.
Topics: Adolescent; Chorea; Dystonia Musculorum Deformans; Dystonic Disorders; Genetic Diseases, X-Linked; H | 1963 |
[COMPLICATIONS OF NEUROLEPTICS].
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Parkinsonian Disorders; Phenothiazines; Prochlorp | 1963 |
MEBUTAMATE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Antihypertensive Agents; Arthritis; Arthritis, Rheumatoid; Blood Pressure Determination; Carbamates; | 1964 |
PARKINSONISM: AETIOLOGY AND TREATMENT.
Topics: Carbon Monoxide Poisoning; Craniocerebral Trauma; Drug Therapy; Encephalitis; Intracranial Arteriosc | 1964 |
AN EXPERIMENTAL STUDY OF THE NEUROPATHOLOGICAL AND TOXICOLOGICAL EFFECTS OF CHLORPROMAZINE AND RESERPINE.
Topics: Cerebellum; Cerebrovascular Circulation; Chlorpromazine; Guinea Pigs; Nervous System Diseases; Parki | 1964 |
EFFERENT MUSCLE INNERVATION AND RIGIDITY.
Topics: Anatomy; Autonomic Nerve Block; Catecholamines; Electromyography; Electrophysiology; Metabolism; Mus | 1964 |
TREMORINE-INDUCED TREMOR VERSUS EXTRAPYRAMIDAL DISEASE.
Topics: Anura; Diarrhea; Exophthalmos; Extrapyramidal Tracts; Heterocyclic Compounds; Hypothalamus; Mice; Pa | 1964 |
[OCULAR PRESSURE, NEUROLEPTIC AGENTS AND PARKINSONIAN STATES].
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Intraocular Pressure; Methotrimeprazine; Parkinso | 1963 |
[ON THE ANTAGONISM OF THE ACTION OF NEUROLEPTICS AND ANTIPARKINSON AGENTS].
Topics: Antiparkinson Agents; Antipsychotic Agents; Chlorpromazine; Handwriting; Humans; Movement Disorders; | 1964 |
AN APPARENTLY IRREVERSIBLE SYNDROME OF ABNORMAL MOVEMENTS FOLLOWING PHENOTHIAZINE MEDICATION.
Topics: Brain; Brain Damage, Chronic; Brain Diseases; Chlorpromazine; Chorea; Diagnosis, Differential; Elect | 1964 |
MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN.
Topics: Animals; Atropine; Behavior, Animal; Brain; Brain Chemistry; Cats; Caudate Nucleus; Cerebral Cortex; | 1965 |
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson | 1964 |
RESERPINE-NICOTINE INDUCED PARKINSONISM IN MICE.
Topics: Anticonvulsants; Atropine; Lactose; Mice; Muscle Relaxants, Central; Neostigmine; Nicotine; Parkinso | 1965 |
Dual effect of high-frequency stimulation on subthalamic neuron activity.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Animals; Calcium Channel Blockers; Calcium Channels | 2003 |
Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice.
Topics: Animals; Catalepsy; Female; Haloperidol; Male; Medicine, Ayurvedic; Mice; Parkinsonian Disorders; Ph | 2006 |
Effects of reserpine on the plus-maze discriminative avoidance task: dissociation between memory and motor impairments.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Avoidance Learning; Discrimination Lear | 2006 |
Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Hydroxyl Radical; Ile | 2007 |
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Catalepsy; Dopamine Agonists; Indoles; Macaca fascicul | 2000 |
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Benzazepines; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine Ag | 2000 |
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Comb | 2001 |
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Animals; Behavior, Anima | 2001 |
A simple method to measure stride length as an index of nigrostriatal dysfunction in mice.
Topics: Animals; Antipsychotic Agents; Benserazide; Convulsants; Corpus Striatum; Dopamine Agents; Dopamine | 2002 |
Behavioral effects of MK-801 on reserpine-treated mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, | 2002 |